董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul B. Bolno | 男 | Director,Chief Executive Officer and President | 52 | 1227.79万美元 | 304.98 | 2026-11-12 |
| Ken Takanashi | 男 | Independent Director | 62 | 51.50万美元 | 980.09 | 2026-11-12 |
| Heidi L. Wagner | 女 | Independent Director | 62 | 53.00万美元 | 25.16 | 2026-11-12 |
| Christian Henry | 男 | Chair of the Board and Independent Director | 58 | 56.56万美元 | 14.21 | 2026-11-12 |
| Adrian Rawcliffe | 男 | Independent Director | 54 | 53.50万美元 | 17.44 | 2026-11-12 |
| Aik Na Tan | 女 | Independent Director | 56 | 98.99万美元 | 8.85 | 2026-11-12 |
| Mark H. N. Corrigan | 男 | Independent Director | 69 | 54.00万美元 | 23.55 | 2026-11-12 |
| Gregory L. Verdine | 男 | Director | 67 | 51.50万美元 | 60.31 | 2026-11-12 |
| Peter Kolchinsky | 男 | Independent Director | 50 | 51.50万美元 | 3427.24 | 2026-11-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul B. Bolno | 男 | Director,Chief Executive Officer and President | 52 | 1227.79万美元 | 304.98 | 2026-11-12 |
| Christopher Francis | 男 | Chief Strategy Officer | 48 | 246.59万美元 | 20.02 | 2026-11-12 |
| Kyle Moran | 男 | Chief Financial Officer | 56 | 375.33万美元 | 70.22 | 2026-11-12 |
| Chandra Vargeese | 女 | Chief Technology Officer and Head of Platform Discovery Sciences | 65 | 340.04万美元 | 134.10 | 2026-11-12 |
| Erik Ingelsson | 男 | Chief Scientific Officer | 51 | 未披露 | 未持股 | 2026-11-12 |
| Chris Wright | 男 | Chief Medical Officer | 61 | 未披露 | 未持股 | 2026-11-12 |
董事简历
中英对照 | 中文 | 英文- Paul B. Bolno
-
Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
Paul B. Bolno has served as President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining Wave Life Sciences, Inc., he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine. - Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
- Paul B. Bolno has served as President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining Wave Life Sciences, Inc., he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
- Ken Takanashi
-
Ken Takanashi，自2012年7月在公司董事会工作。2002年Takanashi先生担任Shin Nippon Biomedical Laboratories Ltd.（SNBL）和子公司的不同的执行管理和董事职位，目前担任监督业务部门高级管理董事。Takanashi先生担任SNBL USA, Ltd.（Shin Nippon Biomedical Laboratories的子公司）的财务总监（2012-2014年）。他拥有华威大学（University of Warwick）工商管理硕士学位和东京大学（University of Tokyo）学士学位，他也是一名注册会计师。
Ken Takanashi has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Vice Chairman. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of SNBL, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly traded and became a privately held company and wholly owned subsidiary of SNBL on June 8, 2023. Since 2020, Mr. Takanashi has served as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, in addition to serving as a member of the board of directors of a number of privately held companies. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant. - Ken Takanashi，自2012年7月在公司董事会工作。2002年Takanashi先生担任Shin Nippon Biomedical Laboratories Ltd.（SNBL）和子公司的不同的执行管理和董事职位，目前担任监督业务部门高级管理董事。Takanashi先生担任SNBL USA, Ltd.（Shin Nippon Biomedical Laboratories的子公司）的财务总监（2012-2014年）。他拥有华威大学（University of Warwick）工商管理硕士学位和东京大学（University of Tokyo）学士学位，他也是一名注册会计师。
- Ken Takanashi has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Vice Chairman. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of SNBL, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly traded and became a privately held company and wholly owned subsidiary of SNBL on June 8, 2023. Since 2020, Mr. Takanashi has served as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, in addition to serving as a member of the board of directors of a number of privately held companies. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant.
- Heidi L. Wagner
-
Heidi L. Wagner，自2019年9月起担任董事。Wagner女士目前担任ElevateBio, LLC（一家私营生物制药公司）的全球政府事务主管（自2023年3月以来）。Wagner女士还担任the University of Colorado Foundation的董事会成员。Wagner女士从2018年到2021年1月担任Global Blood Therapeutics, Inc.的政府事务和政策高级副总裁。在加入Global Blood Therapeutics之前，Wagner女士曾担任Alexion Pharmaceuticals, Inc.的全球政府事务高级副总裁和执行委员会成员（2012年至2018年），以及全球政府事务副总裁（2009年至2012年）。Wagner女士从2000年到2009年担任Genentech, Inc.的政府事务高级总监，从1998年到1999年担任政府事务总监。在此之前，她曾担任医疗保健领导委员会的卫生政策主任和顾问，并在Epstein Becker & Green和Groom & Nordberg以及美国众议院担任各种职务。Wagner女士目前担任the American Kidney Fund的董事会成员、the University of Colorado Foundation的受托人、the University of Colorado, College of Media, Communication and Information的顾问委员会成员。从2015年到2018年，她还担任欧洲制药企业家联合会的董事会成员。Wagner女士在George Mason University法学院获得法学博士学位，并在University of Colorado获得新闻和大众传播理学学士学位。
Heidi L. Wagner has served as a director since September 2019. Ms. Wagner previously served as Global Head of Government Affairs at ElevateBio, LLC, a privately held biopharmaceutical company, from March 2023 through October 2025. Ms. Wagner served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., from 2018 through January 2021. Prior to joining Global Blood Therapeutics, Ms. Wagner served as Senior Vice President, Global Governmental Affairs and a member of the Executive Committee at Alexion Pharmaceuticals, Inc. from 2012 to 2018, and as Vice President, Global Government Affairs from 2009 to 2012. Ms. Wagner held the role of Senior Director of Government Affairs at Genentech, Inc. from 2000 to 2009, and as Director, Government Affairs from 1998 to 1999. Prior to that time, she served as Health Policy Director and Consultant at Healthcare Leadership Council, and in various roles at Epstein Becker & Green and Groom & Nordberg, and the U.S. House of Representatives. Ms. Wagner currently serves a board member of the non profit organization, No Patient Left Behind, in addition to serving as a member of the board of directors of the Lieber Institute for Brain Development, and as a member of the board of directors and as a Trustee for the University of Colorado Foundation. From 2015 to 2018, she also served as a member of the board of directors of the European Confederation of Pharmaceutical Entrepreneurs. Ms. Wagner earned a J.D. from George Mason University School of Law and received a Bachelor of Science in Journalism and Mass Communication from the University of Colorado. - Heidi L. Wagner，自2019年9月起担任董事。Wagner女士目前担任ElevateBio, LLC（一家私营生物制药公司）的全球政府事务主管（自2023年3月以来）。Wagner女士还担任the University of Colorado Foundation的董事会成员。Wagner女士从2018年到2021年1月担任Global Blood Therapeutics, Inc.的政府事务和政策高级副总裁。在加入Global Blood Therapeutics之前，Wagner女士曾担任Alexion Pharmaceuticals, Inc.的全球政府事务高级副总裁和执行委员会成员（2012年至2018年），以及全球政府事务副总裁（2009年至2012年）。Wagner女士从2000年到2009年担任Genentech, Inc.的政府事务高级总监，从1998年到1999年担任政府事务总监。在此之前，她曾担任医疗保健领导委员会的卫生政策主任和顾问，并在Epstein Becker & Green和Groom & Nordberg以及美国众议院担任各种职务。Wagner女士目前担任the American Kidney Fund的董事会成员、the University of Colorado Foundation的受托人、the University of Colorado, College of Media, Communication and Information的顾问委员会成员。从2015年到2018年，她还担任欧洲制药企业家联合会的董事会成员。Wagner女士在George Mason University法学院获得法学博士学位，并在University of Colorado获得新闻和大众传播理学学士学位。
- Heidi L. Wagner has served as a director since September 2019. Ms. Wagner previously served as Global Head of Government Affairs at ElevateBio, LLC, a privately held biopharmaceutical company, from March 2023 through October 2025. Ms. Wagner served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., from 2018 through January 2021. Prior to joining Global Blood Therapeutics, Ms. Wagner served as Senior Vice President, Global Governmental Affairs and a member of the Executive Committee at Alexion Pharmaceuticals, Inc. from 2012 to 2018, and as Vice President, Global Government Affairs from 2009 to 2012. Ms. Wagner held the role of Senior Director of Government Affairs at Genentech, Inc. from 2000 to 2009, and as Director, Government Affairs from 1998 to 1999. Prior to that time, she served as Health Policy Director and Consultant at Healthcare Leadership Council, and in various roles at Epstein Becker & Green and Groom & Nordberg, and the U.S. House of Representatives. Ms. Wagner currently serves a board member of the non profit organization, No Patient Left Behind, in addition to serving as a member of the board of directors of the Lieber Institute for Brain Development, and as a member of the board of directors and as a Trustee for the University of Colorado Foundation. From 2015 to 2018, she also served as a member of the board of directors of the European Confederation of Pharmaceutical Entrepreneurs. Ms. Wagner earned a J.D. from George Mason University School of Law and received a Bachelor of Science in Journalism and Mass Communication from the University of Colorado.
- Christian Henry
-
Christian Henry自2016年11月起担任董事，自2017年10月起担任Wave Life Sciences公司董事会主席。Henry先生目前担任生命科学上市公司太平洋生物科学的总裁兼首席执行官，他自2020年9月起担任该职位，并自2018年起在其董事会任职。Henry先生自2016年起在合成生物学上市公司Ginkgo Bioworks的董事会任职，此前曾于2021年4月至2021年12月在特殊目的收购上市公司CM Life Sciences III Inc.的董事会任职。Henry先生于2015年至2017年1月担任依诺米那，Inc.执行副总裁兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁兼Genomic Solutions总经理，2010年至2012年担任高级副总裁、首席财务官 & Life Sciences总经理，2009年至2010年担任企业发展高级副总裁兼首席财务官,2007年至2009年担任高级副总裁兼首席财务官,2005年至2006年担任副总裁兼首席财务官。在加入Illumina, Inc.之前，Henry先生于2003年至2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任Affymetrix, Inc.（于2016年被赛默飞世尔收购）的副总裁、财务兼公司控制人。1997年，Henry先生加入内克塔治疗（前身为Inhale Therapeutic Systems，Inc.），担任公司控制人，后于1997年至1999年担任首席会计官。1996年，Henry先生担任Sugen，Inc.的总会计经理。Henry先生于1992年在Ernst & Young LLP开始了他的职业生涯，他在该公司担任高级会计师直至1996年。Henry先生在加州大学圣地亚哥分校获得生物化学和细胞生物学学士学位，在加州大学欧文分校获得金融学硕士学位。
Christian Henry has served as a director since November 2016, and as Chair of Board since October 2017. Mr. Henry previously served as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, from September 2020 to August 2026; Mr. Henry continues to serve on its board of directors, a position he has held since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly traded synthetic biology company, since 2016, and previously served on the board of directors of CM Life Sciences III Inc., a publicly traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. - Christian Henry自2016年11月起担任董事，自2017年10月起担任Wave Life Sciences公司董事会主席。Henry先生目前担任生命科学上市公司太平洋生物科学的总裁兼首席执行官，他自2020年9月起担任该职位，并自2018年起在其董事会任职。Henry先生自2016年起在合成生物学上市公司Ginkgo Bioworks的董事会任职，此前曾于2021年4月至2021年12月在特殊目的收购上市公司CM Life Sciences III Inc.的董事会任职。Henry先生于2015年至2017年1月担任依诺米那，Inc.执行副总裁兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁兼Genomic Solutions总经理，2010年至2012年担任高级副总裁、首席财务官 & Life Sciences总经理，2009年至2010年担任企业发展高级副总裁兼首席财务官,2007年至2009年担任高级副总裁兼首席财务官,2005年至2006年担任副总裁兼首席财务官。在加入Illumina, Inc.之前，Henry先生于2003年至2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任Affymetrix, Inc.（于2016年被赛默飞世尔收购）的副总裁、财务兼公司控制人。1997年，Henry先生加入内克塔治疗（前身为Inhale Therapeutic Systems，Inc.），担任公司控制人，后于1997年至1999年担任首席会计官。1996年，Henry先生担任Sugen，Inc.的总会计经理。Henry先生于1992年在Ernst & Young LLP开始了他的职业生涯，他在该公司担任高级会计师直至1996年。Henry先生在加州大学圣地亚哥分校获得生物化学和细胞生物学学士学位，在加州大学欧文分校获得金融学硕士学位。
- Christian Henry has served as a director since November 2016, and as Chair of Board since October 2017. Mr. Henry previously served as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, from September 2020 to August 2026; Mr. Henry continues to serve on its board of directors, a position he has held since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly traded synthetic biology company, since 2016, and previously served on the board of directors of CM Life Sciences III Inc., a publicly traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine.
- Adrian Rawcliffe
-
Adrian Rawcliffe自2017年2月起担任董事。自2026年1月起，Rawcliffe先生担任私人控股的生物技术公司Etiome Inc.的首席执行官合伙人兼首席执行官。自2019年9月至2025年11月，Rawcliffe先生担任Adaptimmune治疗 PLC.（“Adaptimmune”）的首席执行官和董事会成员，该公司是一家临床阶段生物制药公司，在纳斯达克全球精选市场交易，直至2025年11月。Rawcliffe先生还曾于2016年至2025年11月担任Adaptimmune Ltd.的董事会成员，该公司是一家私人控股公司，是Adaptimmune的子公司。2015年至2019年9月担任Adaptimmune的首席财务官。在加入Adaptimmune之前，Rawcliffe先生曾在葛兰素史克公司担任多个职务，包括2011年至2015年担任财务、北美制药和全球特许经营高级副总裁；2006年至2011年担任全球业务发展和研发财务高级副总裁；2003年至2005年担任全球业务发展交易和风险投资副总裁；2001年至2003年担任交易结构副总裁。2005年至2006年，Rawcliffe先生担任SROne Ltd.总裁兼管理合伙人。Rawcliffe先生的职业生涯始于1993年至1997年在Coopers & Lybrand（现为普华永道）担任监事。Rawcliffe先生在英国达勒姆大学获得自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计师培训。
Adrian Rawcliffe has served as a director since February 2017. Since January 2026, Mr. Rawcliffe has served as CEO Partner and Chief Executive Officer of Etiome Inc., a privately held biotechnology company. Since September 2026, Mr. Rawcliffe has also served on the board of directors of Prologue Medicines, a privately held biotechnology company. From September 2019 to November 2025, Mr. Rawcliffe served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc. ("Adaptimmune"), a clinical stage biopharmaceutical company traded on The Nasdaq Global Select Market until November 2025. Mr. Rawcliffe also served on the board of directors of Adaptimmune Ltd., a privately held company and subsidiary of Adaptimmune from 2016 to November 2025. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW). - Adrian Rawcliffe自2017年2月起担任董事。自2026年1月起，Rawcliffe先生担任私人控股的生物技术公司Etiome Inc.的首席执行官合伙人兼首席执行官。自2019年9月至2025年11月，Rawcliffe先生担任Adaptimmune治疗 PLC.（“Adaptimmune”）的首席执行官和董事会成员，该公司是一家临床阶段生物制药公司，在纳斯达克全球精选市场交易，直至2025年11月。Rawcliffe先生还曾于2016年至2025年11月担任Adaptimmune Ltd.的董事会成员，该公司是一家私人控股公司，是Adaptimmune的子公司。2015年至2019年9月担任Adaptimmune的首席财务官。在加入Adaptimmune之前，Rawcliffe先生曾在葛兰素史克公司担任多个职务，包括2011年至2015年担任财务、北美制药和全球特许经营高级副总裁；2006年至2011年担任全球业务发展和研发财务高级副总裁；2003年至2005年担任全球业务发展交易和风险投资副总裁；2001年至2003年担任交易结构副总裁。2005年至2006年，Rawcliffe先生担任SROne Ltd.总裁兼管理合伙人。Rawcliffe先生的职业生涯始于1993年至1997年在Coopers & Lybrand（现为普华永道）担任监事。Rawcliffe先生在英国达勒姆大学获得自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计师培训。
- Adrian Rawcliffe has served as a director since February 2017. Since January 2026, Mr. Rawcliffe has served as CEO Partner and Chief Executive Officer of Etiome Inc., a privately held biotechnology company. Since September 2026, Mr. Rawcliffe has also served on the board of directors of Prologue Medicines, a privately held biotechnology company. From September 2019 to November 2025, Mr. Rawcliffe served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc. ("Adaptimmune"), a clinical stage biopharmaceutical company traded on The Nasdaq Global Select Market until November 2025. Mr. Rawcliffe also served on the board of directors of Adaptimmune Ltd., a privately held company and subsidiary of Adaptimmune from 2016 to November 2025. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW).
- Aik Na Tan
-
Aik Na Tan自2020年8月起担任董事。Tan女士目前担任新加坡南洋理工大学（“南大”）高级副校长（行政），自2020年1月起担任该职位。自2016年8月加入南大至2017年12月，她担任南大首席财务官。她还曾于2017年4月至2017年12月担任南大首席行政官，并于2018年1月至2019年12月担任南大副校长（行政）。在加入南大之前，Tan女士曾于2015年至2016年担任全球金融转型负责人兼从杜邦分拆出来的Chemours公司Singapore Pte Ltd的董事总经理。从1994年到2015年，Tan女士在杜邦公司担任过许多全球和区域领导职务，包括会计、企业金库、六西格玛、财务系统、供应链、运营、财务和战略规划，包括在杜邦公司（新加坡）私人有限公司担任多个职位，最近于2011年11月至2015年2月担任杜邦钛业技术公司的首席财务官。谭女士的职业生涯始于普华永道的税务助理。Tan女士拥有新加坡南洋理工大学会计学学士学位，并且是新加坡特许会计师协会的成员。
Aik Na Tan has served as a director since August 2020. Ms. Tan currently serves as Senior Vice President (Administration) at Nanyang Technological University, Singapore (NTU), a position she has held since January 2020. From when she joined NTU in August 2016 to December 2017, she served as NTU's Chief Financial Officer. She also served as NTU's Chief Administrative Officer from April 2017 to December 2017 and as NTU's Vice President (Administration) from January 2018 to December 2019. Prior to joining NTU, Ms. Tan served as Global Finance Transformation Leader & Managing Director of the Chemours Company Singapore Pte Ltd, a spin off from DuPont, from 2015 to 2016. From 1994 to 2015, Ms. Tan held numerous global and regional leadership roles at DuPont in accounting, corporate treasury, six sigma, financial systems, supply chain, operations, financial and strategic planning, including various positions at DuPont Company (Singapore) Pte Ltd, most recently serving as the Chief Financial Officer of DuPont Titanium Technologies from November 2011 to February 2015. Ms. Tan began her professional career as a tax assistant at Price Waterhouse. Ms. Tan holds a Bachelor of Accountancy degree from the Nanyang Technological University, Singapore, and is a member of the Institute of Singapore Chartered Accountants. - Aik Na Tan自2020年8月起担任董事。Tan女士目前担任新加坡南洋理工大学（“南大”）高级副校长（行政），自2020年1月起担任该职位。自2016年8月加入南大至2017年12月，她担任南大首席财务官。她还曾于2017年4月至2017年12月担任南大首席行政官，并于2018年1月至2019年12月担任南大副校长（行政）。在加入南大之前，Tan女士曾于2015年至2016年担任全球金融转型负责人兼从杜邦分拆出来的Chemours公司Singapore Pte Ltd的董事总经理。从1994年到2015年，Tan女士在杜邦公司担任过许多全球和区域领导职务，包括会计、企业金库、六西格玛、财务系统、供应链、运营、财务和战略规划，包括在杜邦公司（新加坡）私人有限公司担任多个职位，最近于2011年11月至2015年2月担任杜邦钛业技术公司的首席财务官。谭女士的职业生涯始于普华永道的税务助理。Tan女士拥有新加坡南洋理工大学会计学学士学位，并且是新加坡特许会计师协会的成员。
- Aik Na Tan has served as a director since August 2020. Ms. Tan currently serves as Senior Vice President (Administration) at Nanyang Technological University, Singapore (NTU), a position she has held since January 2020. From when she joined NTU in August 2016 to December 2017, she served as NTU's Chief Financial Officer. She also served as NTU's Chief Administrative Officer from April 2017 to December 2017 and as NTU's Vice President (Administration) from January 2018 to December 2019. Prior to joining NTU, Ms. Tan served as Global Finance Transformation Leader & Managing Director of the Chemours Company Singapore Pte Ltd, a spin off from DuPont, from 2015 to 2016. From 1994 to 2015, Ms. Tan held numerous global and regional leadership roles at DuPont in accounting, corporate treasury, six sigma, financial systems, supply chain, operations, financial and strategic planning, including various positions at DuPont Company (Singapore) Pte Ltd, most recently serving as the Chief Financial Officer of DuPont Titanium Technologies from November 2011 to February 2015. Ms. Tan began her professional career as a tax assistant at Price Waterhouse. Ms. Tan holds a Bachelor of Accountancy degree from the Nanyang Technological University, Singapore, and is a member of the Institute of Singapore Chartered Accountants.
- Mark H. N. Corrigan
-
Mark H. N. Corrigan， 硕士学位。a Class II类董事，自2009年12月起担任 Zalicus董事。自2010年1月起担任 Zalicus总裁和首席执行官。2003年4月到2009年12月担任Sepracor Inc.（一家公开上市制造公司）研发部执行副总裁。加入Sepracor Inc.之前，他在Pharmacia & Upjohn（一家公开上市制造公司，2002年被Pfizer, Inc.收购）工作10年，最近的职位是担任 Global Clinical Research and Experimental Medicine集团副总裁。加入制药行业之前，他在the University of North Carolina Medical School进行5年的学术研究，主要研究心理神经内分泌学。他还担任 Cubist Pharmaceuticals, Inc.（一家公开上市生物制药公司）董事。他持有佛吉尼亚大学（the University of Virginia）文学学士学位以及硕士学位，之后不久还在 Cornell and Maine Medical Center受到了精神病学的特殊训练。
Mark H. N. Corrigan has served as a director since September 2019. Dr. Corrigan currently serves on the board of directors of AstronauTx LLC, a privately held company. Dr. Corrigan also serves as a Strategic Advisor to Ceretype Neuromedicine. Dr. Corrigan served as a member of the board of directors of Silver Creek Pharmaceuticals, Inc., a privately held company, from November 2024 to May 2025 and of Nabriva Therapeutics plc, a publicly traded commercial stage biopharmaceutical company, from June 2021 to December 2023, and previously served on Nabriva's board of directors from June 2017 to May 2020. Dr. Corrigan also served as chairman of the board of directors of Elios Therapeutics, LLC, a privately held development stage immuno oncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. ("Correvio"), from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co founder) from 2016 to March 2019. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia. - Mark H. N. Corrigan， 硕士学位。a Class II类董事，自2009年12月起担任 Zalicus董事。自2010年1月起担任 Zalicus总裁和首席执行官。2003年4月到2009年12月担任Sepracor Inc.（一家公开上市制造公司）研发部执行副总裁。加入Sepracor Inc.之前，他在Pharmacia & Upjohn（一家公开上市制造公司，2002年被Pfizer, Inc.收购）工作10年，最近的职位是担任 Global Clinical Research and Experimental Medicine集团副总裁。加入制药行业之前，他在the University of North Carolina Medical School进行5年的学术研究，主要研究心理神经内分泌学。他还担任 Cubist Pharmaceuticals, Inc.（一家公开上市生物制药公司）董事。他持有佛吉尼亚大学（the University of Virginia）文学学士学位以及硕士学位，之后不久还在 Cornell and Maine Medical Center受到了精神病学的特殊训练。
- Mark H. N. Corrigan has served as a director since September 2019. Dr. Corrigan currently serves on the board of directors of AstronauTx LLC, a privately held company. Dr. Corrigan also serves as a Strategic Advisor to Ceretype Neuromedicine. Dr. Corrigan served as a member of the board of directors of Silver Creek Pharmaceuticals, Inc., a privately held company, from November 2024 to May 2025 and of Nabriva Therapeutics plc, a publicly traded commercial stage biopharmaceutical company, from June 2021 to December 2023, and previously served on Nabriva's board of directors from June 2017 to May 2020. Dr. Corrigan also served as chairman of the board of directors of Elios Therapeutics, LLC, a privately held development stage immuno oncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. ("Correvio"), from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co founder) from 2016 to March 2019. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia.
- Gregory L. Verdine
-
Gregory L. Verdine，他是Wave Life Sciences Ltd.的创始人之一，自2013年7月起担任Wave Life Sciences Ltd. 董事。从Wave Life Sciences Ltd.成立到2013年12月担任总裁、首席执行官和首席科学官，并担任Wave Life Sciences Ltd.董事长。2013年7月至2017年9月担任董事会成员。1989年以来，他曾担任哈佛大学和哈佛医学院干细胞和再生生物系、化学和化学生物系的欧文化学教授；他现在是欧文化学荣誉教授。Verdine博士于2013年共同创立了非营利性的Gloucester Marine Genomics Institute和Gloucester Biotechnology Academy，并担任创始总裁直到2016年。他是Fog Pharmaceuticals Inc.（一家私营公司）的联合创始人，目前担任该公司的董事会副主席。他也是私人控股公司LifeMine Therapeutics Inc.的总裁兼首席执行官和董事会成员。他也是Warp Drive Bio（与Revolution Medicines, Inc.（纳斯达克股票代码：RVMD）合并）的创始人，并从公司2012年成立到2016年4月担任各种职务，从首席科学官到首席执行官。Verdine博士创立了Enanta制药公司，并从1990年到2013年首次公开募股担任其董事会成员。他曾担任WuXi Healthcare Ventures、AppleTree Ventures、TPG Biotech和Third Rock Ventures的风险合伙人。他曾任职于美国国家癌症研究所的科学顾问委员会，Memorial Sloan Kettering癌症中心的科学顾问委员会，并曾担任Shin Nippon Biomedical Laboratories Ltd, Hofmann La Roche, Pfizer和Merck的高级顾问。他也是Eleven Biotherapeutics、Tokai Therapeutics、Aileron Therapeutics和Gloucester Pharmaceuticals（2010年被Celgene收购）的联合创始人。他还曾担任the Dana-Farber Cancer Institute的化学生物学倡议和癌症化学生物学项目的董事。他在哥伦比亚大学获得化学博士学位，并在麻省理工学院和哈佛医学院完成了分子生物学的博士后工作。
Gregory L. Verdine Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co founded the non profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the co founder of Parabilis Medicines (formerly Fog Pharmaceuticals Inc.), a privately held company, and served as President and Chief Executive Officer of the company from October 2015 to June 2023 and Vice Chairman of the Board of Directors from June 2023 to June 2024. Dr. Verdine serves as President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc., DoveTree Medicines LLC, and DoveTree Unus, Inc., privately held companies. Since August 2024, Dr. Verdine has served as Executive Chair at Biggie Bio, LLC and as sole Director of wholly owned subsidiary VidaVinci, Inc., both privately held companies. Since 2025, Dr. Verdine has served as the Executive Chair at RococoBio, LLC, and since 2024, as a board member of Stipple Bio, Inc. Dr. Verdine is a co owner of Lola Advisors and serves as Managing General Partner of LoLa Capital Partners, a new modality venture capital fund, and also serves as a consultant at Yael Capital Management Ltd., as well as XtalPi, a publicly traded company on the Hong Kong Stock Exchange. He is also the founder of Warp Drive Bio (merged into Revolution Medicines, Inc. (Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company's inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures, and he is currently a Venture Partner at Andreessen Horowitz. He has served on the Board of Scientific Counselors of the National Cancer Institute, and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and was a Senior Advisor to SNBL, Hofmann La Roche, Pfizer and Merck. Dr. Verdine is also a co founder of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana Farber Cancer Institute. Dr. Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral work in Molecular Biology at the Massachusetts Institute of Technology and Harvard Medical School. - Gregory L. Verdine，他是Wave Life Sciences Ltd.的创始人之一，自2013年7月起担任Wave Life Sciences Ltd. 董事。从Wave Life Sciences Ltd.成立到2013年12月担任总裁、首席执行官和首席科学官，并担任Wave Life Sciences Ltd.董事长。2013年7月至2017年9月担任董事会成员。1989年以来，他曾担任哈佛大学和哈佛医学院干细胞和再生生物系、化学和化学生物系的欧文化学教授；他现在是欧文化学荣誉教授。Verdine博士于2013年共同创立了非营利性的Gloucester Marine Genomics Institute和Gloucester Biotechnology Academy，并担任创始总裁直到2016年。他是Fog Pharmaceuticals Inc.（一家私营公司）的联合创始人，目前担任该公司的董事会副主席。他也是私人控股公司LifeMine Therapeutics Inc.的总裁兼首席执行官和董事会成员。他也是Warp Drive Bio（与Revolution Medicines, Inc.（纳斯达克股票代码：RVMD）合并）的创始人，并从公司2012年成立到2016年4月担任各种职务，从首席科学官到首席执行官。Verdine博士创立了Enanta制药公司，并从1990年到2013年首次公开募股担任其董事会成员。他曾担任WuXi Healthcare Ventures、AppleTree Ventures、TPG Biotech和Third Rock Ventures的风险合伙人。他曾任职于美国国家癌症研究所的科学顾问委员会，Memorial Sloan Kettering癌症中心的科学顾问委员会，并曾担任Shin Nippon Biomedical Laboratories Ltd, Hofmann La Roche, Pfizer和Merck的高级顾问。他也是Eleven Biotherapeutics、Tokai Therapeutics、Aileron Therapeutics和Gloucester Pharmaceuticals（2010年被Celgene收购）的联合创始人。他还曾担任the Dana-Farber Cancer Institute的化学生物学倡议和癌症化学生物学项目的董事。他在哥伦比亚大学获得化学博士学位，并在麻省理工学院和哈佛医学院完成了分子生物学的博士后工作。
- Gregory L. Verdine Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co founded the non profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the co founder of Parabilis Medicines (formerly Fog Pharmaceuticals Inc.), a privately held company, and served as President and Chief Executive Officer of the company from October 2015 to June 2023 and Vice Chairman of the Board of Directors from June 2023 to June 2024. Dr. Verdine serves as President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc., DoveTree Medicines LLC, and DoveTree Unus, Inc., privately held companies. Since August 2024, Dr. Verdine has served as Executive Chair at Biggie Bio, LLC and as sole Director of wholly owned subsidiary VidaVinci, Inc., both privately held companies. Since 2025, Dr. Verdine has served as the Executive Chair at RococoBio, LLC, and since 2024, as a board member of Stipple Bio, Inc. Dr. Verdine is a co owner of Lola Advisors and serves as Managing General Partner of LoLa Capital Partners, a new modality venture capital fund, and also serves as a consultant at Yael Capital Management Ltd., as well as XtalPi, a publicly traded company on the Hong Kong Stock Exchange. He is also the founder of Warp Drive Bio (merged into Revolution Medicines, Inc. (Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company's inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures, and he is currently a Venture Partner at Andreessen Horowitz. He has served on the Board of Scientific Counselors of the National Cancer Institute, and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and was a Senior Advisor to SNBL, Hofmann La Roche, Pfizer and Merck. Dr. Verdine is also a co founder of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana Farber Cancer Institute. Dr. Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral work in Molecular Biology at the Massachusetts Institute of Technology and Harvard Medical School.
- Peter Kolchinsky
-
Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
Peter Kolchinsky has served as a director since January 2015. Dr. Kolchinsky is a founder and Managing Partner of RA Capital, a multi stage investment manager which is dedicated to evidence based investing in healthcare and life science companies that are developing drugs, medical devices, diagnostics, services and research tools, where he has worked since 2001. RA Capital is the investment manager of RA Capital Healthcare Fund, L.P. Dr. Kolchinsky has served as a member of the board of directors of ARS Pharmaceuticals Inc., a publicly traded biopharmaceutical company, since August 2021, in addition to serving as a member of the board of directors of a number of privately held companies. He is the founder and currently serves on the advisory board of the non profit organization, No Patient Left Behind. Dr. Kolchinsky previously served as a member of the board of directors of Forma Therapeutics Holdings, Inc., from December 2019 through October 2022, Dicerna Pharmaceuticals, Inc., from July 2013 to December 2019, Icosavax, Inc. from July 2021 to December 2023, Research Alliance Corporation I from April 2020 to June 2021, Research Alliance Corporation II from July 2020 to December 2022, and Synthorx, Inc., from May 2018 to January 2020, all of which were publicly traded biopharmaceutical companies. Dr. Kolchinsky also leads RA Capital's engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor's degree in Biology from Cornell University. - Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
- Peter Kolchinsky has served as a director since January 2015. Dr. Kolchinsky is a founder and Managing Partner of RA Capital, a multi stage investment manager which is dedicated to evidence based investing in healthcare and life science companies that are developing drugs, medical devices, diagnostics, services and research tools, where he has worked since 2001. RA Capital is the investment manager of RA Capital Healthcare Fund, L.P. Dr. Kolchinsky has served as a member of the board of directors of ARS Pharmaceuticals Inc., a publicly traded biopharmaceutical company, since August 2021, in addition to serving as a member of the board of directors of a number of privately held companies. He is the founder and currently serves on the advisory board of the non profit organization, No Patient Left Behind. Dr. Kolchinsky previously served as a member of the board of directors of Forma Therapeutics Holdings, Inc., from December 2019 through October 2022, Dicerna Pharmaceuticals, Inc., from July 2013 to December 2019, Icosavax, Inc. from July 2021 to December 2023, Research Alliance Corporation I from April 2020 to June 2021, Research Alliance Corporation II from July 2020 to December 2022, and Synthorx, Inc., from May 2018 to January 2020, all of which were publicly traded biopharmaceutical companies. Dr. Kolchinsky also leads RA Capital's engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor's degree in Biology from Cornell University.
高管简历
中英对照 | 中文 | 英文- Paul B. Bolno
Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
Paul B. Bolno has served as President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining Wave Life Sciences, Inc., he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.- Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
- Paul B. Bolno has served as President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining Wave Life Sciences, Inc., he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
- Christopher Francis
Christopher Francis，自2014年4月起担任公司的副总裁和业务拓展负责人。在加入公司之前，他在GlaxoSmithKline Oncology担任高级运恒、战略和拓展职位（2009-2014年），也是建立GlaxoSmithKline的罕见疾病单位的团队成员。在GlaxoSmithKline之前，Francis博士是Two River有限责任公司（Two River LLC）的健康保健私人股权助理（2008-2009年）。他在IMS Health开始他在药物定价和偿还咨询的职业生涯。Francis博士获得了墨尔本大学（University of Melbourne）生物化学和细胞生物的本科和研究生学位，也是剑桥大学（University of Cambridge）博士研究助理。
Christopher Francis has served as Chief Strategy Officer since September 2026. During the period of May 2017 to September 2026, Dr. Francis served as Senior Vice President, Corporate Development, Head of Emerging Areas, and during the period January 2017 to May 2017, he served as Senior Vice President, Corporate Development & Portfolio Management. Prior to that, Dr. Francis served as Vice President, Head of Business Development since April 2014. Prior to joining Wave Life Sciences, Inc., Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established GlaxoSmithKline's Rare Disease Unit. Before GlaxoSmithKline, Dr. Francis was a health care private equity associate at Two River LLC from 2008 to 2009. Dr. Francis has served as a Member of the Investment Review Committee for WEHI Ventures in Australia since 2023. He began his career in pharmaceutical pricing and reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.- Christopher Francis，自2014年4月起担任公司的副总裁和业务拓展负责人。在加入公司之前，他在GlaxoSmithKline Oncology担任高级运恒、战略和拓展职位（2009-2014年），也是建立GlaxoSmithKline的罕见疾病单位的团队成员。在GlaxoSmithKline之前，Francis博士是Two River有限责任公司（Two River LLC）的健康保健私人股权助理（2008-2009年）。他在IMS Health开始他在药物定价和偿还咨询的职业生涯。Francis博士获得了墨尔本大学（University of Melbourne）生物化学和细胞生物的本科和研究生学位，也是剑桥大学（University of Cambridge）博士研究助理。
- Christopher Francis has served as Chief Strategy Officer since September 2026. During the period of May 2017 to September 2026, Dr. Francis served as Senior Vice President, Corporate Development, Head of Emerging Areas, and during the period January 2017 to May 2017, he served as Senior Vice President, Corporate Development & Portfolio Management. Prior to that, Dr. Francis served as Vice President, Head of Business Development since April 2014. Prior to joining Wave Life Sciences, Inc., Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established GlaxoSmithKline's Rare Disease Unit. Before GlaxoSmithKline, Dr. Francis was a health care private equity associate at Two River LLC from 2008 to 2009. Dr. Francis has served as a Member of the Investment Review Committee for WEHI Ventures in Australia since 2023. He began his career in pharmaceutical pricing and reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.
- Kyle Moran
Kyle Moran，自2014年7月起担任公司的副总裁和财务负责人。在加入公司之前，Moran先生担任Veroha股份有限公司（Veroha, Inc.，一家信息保险软件公司，专注于电子公证解决方案）的财务总监和运营总监（2010-2014年）。他也是Context Financial Services有限责任公司（Context Financial Services, LLC，精品咨询公司，给处于快速扩张的初创公司和中型公司提供临时财务总监服务或者需要专业的财务法律顾问）创世合伙人，2006-2014年在那边工作。另外，Moran先生在领先的全球财务服务公司担任高级运营和财务职位，包括Zurich Scudder Investments、JPMorgan Chase和 Putnam Investments。Moran先生拥有波士顿大学（Boston College）经济学学士学位，并参加布兰迪斯大学（Brandeis University）国际经济学和财务的伦贝格（Lemberg）硕士项目。Moran先生是一名注册财务分析师。
Kyle Moran has served as Chief Financial Officer since December 2020. Prior to this appointment, Mr. Moran served as Vice President, Head of Finance from July 2014 to August 2016; Vice President, Technical Operations from August 2016 to December 2017; Senior Vice President, Technical Operations, from December 2017 to November 2018; Senior Vice President, Operations and Business Analytics from November 2018 to January 2020; and most recently as Senior Vice President, Finance and Operations from January 2020 through his promotion to Chief Financial Officer in December 2020. Prior to joining Wave Life Sciences, Inc., Mr. Moran served as Chief Financial Officer and Chief Operating Officer of Veroha, Inc., an information assurance software company focused on electronic notary solutions, from 2010 to 2014. He was also a founding partner of Context Financial Services, LLC, a boutique consulting firm that provided interim CFO services to start up and middle market companies undergoing rapid expansion or needing expert financial counsel and worked there from 2006 to 2014. In addition, Mr. Moran held senior operational and financial roles at leading global financial services firms, including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. Mr. Moran holds a bachelor's degree in Economics from Boston College and attended the Lemberg Master's Program in International Economics and Finance at Brandeis University. Mr. Moran is a Chartered Financial Analyst.- Kyle Moran，自2014年7月起担任公司的副总裁和财务负责人。在加入公司之前，Moran先生担任Veroha股份有限公司（Veroha, Inc.，一家信息保险软件公司，专注于电子公证解决方案）的财务总监和运营总监（2010-2014年）。他也是Context Financial Services有限责任公司（Context Financial Services, LLC，精品咨询公司，给处于快速扩张的初创公司和中型公司提供临时财务总监服务或者需要专业的财务法律顾问）创世合伙人，2006-2014年在那边工作。另外，Moran先生在领先的全球财务服务公司担任高级运营和财务职位，包括Zurich Scudder Investments、JPMorgan Chase和 Putnam Investments。Moran先生拥有波士顿大学（Boston College）经济学学士学位，并参加布兰迪斯大学（Brandeis University）国际经济学和财务的伦贝格（Lemberg）硕士项目。Moran先生是一名注册财务分析师。
- Kyle Moran has served as Chief Financial Officer since December 2020. Prior to this appointment, Mr. Moran served as Vice President, Head of Finance from July 2014 to August 2016; Vice President, Technical Operations from August 2016 to December 2017; Senior Vice President, Technical Operations, from December 2017 to November 2018; Senior Vice President, Operations and Business Analytics from November 2018 to January 2020; and most recently as Senior Vice President, Finance and Operations from January 2020 through his promotion to Chief Financial Officer in December 2020. Prior to joining Wave Life Sciences, Inc., Mr. Moran served as Chief Financial Officer and Chief Operating Officer of Veroha, Inc., an information assurance software company focused on electronic notary solutions, from 2010 to 2014. He was also a founding partner of Context Financial Services, LLC, a boutique consulting firm that provided interim CFO services to start up and middle market companies undergoing rapid expansion or needing expert financial counsel and worked there from 2006 to 2014. In addition, Mr. Moran held senior operational and financial roles at leading global financial services firms, including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. Mr. Moran holds a bachelor's degree in Economics from Boston College and attended the Lemberg Master's Program in International Economics and Finance at Brandeis University. Mr. Moran is a Chartered Financial Analyst.
- Chandra Vargeese
Chandra Vargeese，曾担任Wave Life Sciences Ltd.首席技术官，平台发现科学主管（2020年5月以来）。2014年8月至2020年4月期间，Vargeese博士担任高级副总裁，负责药物发现。加入Wave Life Sciences Ltd.之前，她曾担任Novartis的执行董事兼RNA化学和递送主管（2008年至2014年）。加入Novartis之前，她在Merck & Co.的RNA治疗部门领导siRNA递送，在那里她担任RNA化学和递送的高级董事兼主管。她通过收购Sirna Therapeutics加入Merck & Co.，担任化学副总裁。在Sirna之前，她曾担任NeXstar Pharmaceuticals的化学副总监，也是Macugen （pegaptanib）的共同发明者，Macugen （pegaptanib）是一种被批准用于治疗湿性AMD的疗法。Vargeese博士在印度班加罗尔的印度科学研究所获得有机化学博士学位，并在University of Rhode Island完成博士后工作。
Chandra Vargeese has served as Chief Technology Officer, Head of Platform Discovery Sciences since May 2020. During the period of August 2014 to April 2020, Dr. Vargeese served as Senior Vice President, Head of Drug Discovery. Before joining Wave Life Sciences, Inc., Dr. Vargeese served as Novartis' Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck & Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics ("Sirna"), where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co inventor of Macugen (pegaptanib), an approved therapy for treating wet Age Related Macular Degeneration (AMD). Dr. Vargeese earned a Ph.D. in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post doctoral work at the University of Rhode Island.- Chandra Vargeese，曾担任Wave Life Sciences Ltd.首席技术官，平台发现科学主管（2020年5月以来）。2014年8月至2020年4月期间，Vargeese博士担任高级副总裁，负责药物发现。加入Wave Life Sciences Ltd.之前，她曾担任Novartis的执行董事兼RNA化学和递送主管（2008年至2014年）。加入Novartis之前，她在Merck & Co.的RNA治疗部门领导siRNA递送，在那里她担任RNA化学和递送的高级董事兼主管。她通过收购Sirna Therapeutics加入Merck & Co.，担任化学副总裁。在Sirna之前，她曾担任NeXstar Pharmaceuticals的化学副总监，也是Macugen （pegaptanib）的共同发明者，Macugen （pegaptanib）是一种被批准用于治疗湿性AMD的疗法。Vargeese博士在印度班加罗尔的印度科学研究所获得有机化学博士学位，并在University of Rhode Island完成博士后工作。
- Chandra Vargeese has served as Chief Technology Officer, Head of Platform Discovery Sciences since May 2020. During the period of August 2014 to April 2020, Dr. Vargeese served as Senior Vice President, Head of Drug Discovery. Before joining Wave Life Sciences, Inc., Dr. Vargeese served as Novartis' Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck & Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics ("Sirna"), where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co inventor of Macugen (pegaptanib), an approved therapy for treating wet Age Related Macular Degeneration (AMD). Dr. Vargeese earned a Ph.D. in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post doctoral work at the University of Rhode Island.
- Erik Ingelsson
Erik Ingelsson自2024年5月起担任首席科学官。在加入Wave Life Sciences公司之前，Ingelsson博士曾于2020年1月至2024年5月期间在GSK担任高级副总裁、目标发现负责人；基因组科学高级副总裁；人类遗传学和计算生物学高级副总裁。在GSK期间，他领导的团队专注于GSK治疗领域的大规模、工业化的目标发现和验证方法，包括呼吸系统、免疫学和炎症；肿瘤学；和传染病。在他的角色中，他汇集了人类遗传学、计算生物学、功能基因组学、化学生物学、结构生物学以及蛋白质和细胞科学，以推动药物发现和开发。在加入GSK之前，Ingelsson博士在2016年至2019年期间担任斯坦福大学的医学教授，他的实验室利用人类遗传学和功能基因组学发现了与胰岛素抵抗和相关疾病相关的新的生物学和药物靶点，例如肥胖、MASH和心血管疾病。他的工作将大规模的人类基因组学研究与深入的临床前验证工作和对心脏代谢疾病的重视相结合。Ingelsson博士此前曾于2013年至2016年担任瑞典乌普萨拉大学分子流行病学教授，并于2010年至2012年担任心血管流行病学教授，并于2008年至2010年担任瑞典卡罗林斯卡研究所流行病学副教授。在其职业生涯中，Ingelsson博士曾担任多家公共和私营公司的科学顾问和董事会成员。Ingelsson博士在瑞典乌普萨拉大学获得医学博士学位。他在马萨诸塞州波士顿的弗雷明汉心脏研究中心完成了博士后研究，并在瑞典的耶夫勒和乌普萨拉担任家庭医学的住院医师和研究金，之后他成为了10多年的执业临床医生。
Erik Ingelsson has served as Chief Scientific Officer since May 2024. Prior to joining Wave Life Sciences, Inc., Dr. Ingelsson served as Senior Vice President, Head of Target Discovery; Senior Vice President of Genomic Sciences; and Senior Vice President of Human Genetics and Computational Biology at GSK during the period of January 2020 to May 2024. While at GSK, he led teams focused on a large scale, industrialized approach to target discovery and validation across GSK's therapy areas, including respiratory, immunology and inflammation; oncology; and infectious diseases. In his roles, he brought together human genetics, computational biology, functional genomics, chemical biology, structural biology, and protein and cellular sciences to drive drug discovery and development. Prior to joining GSK, Dr. Ingelsson was Professor of Medicine at Stanford University from 2016 to 2019, where his lab used human genetics and functional genomics to discover novel biology and drug targets related to insulin resistance and related conditions, such as obesity, MASH, and cardiovascular disease. His work combined large scale human genomics studies with in depth preclinical validation work and an emphasis on cardiometabolic diseases. Dr. Ingelsson previously served as Professor of Molecular Epidemiology at Uppsala University, Sweden from 2013 to 2016, and as Professor of Cardiovascular Epidemiology from 2010 to 2012, and as Associate Professor of Epidemiology from 2008 to 2010 at Karolinska Institute, Sweden. Over his career, Dr. Ingelsson has served as scientific advisor and board member for multiple public and private companies. Dr. Ingelsson earned his M.D. and Ph.D. at Uppsala University, Sweden. He completed postdoctoral research at the Framingham Heart Study in Boston, Massachusetts, and held residency and fellowship in Family Medicine at Gavle and Uppsala, Sweden, after which he was a practicing clinician for over 10 years.- Erik Ingelsson自2024年5月起担任首席科学官。在加入Wave Life Sciences公司之前，Ingelsson博士曾于2020年1月至2024年5月期间在GSK担任高级副总裁、目标发现负责人；基因组科学高级副总裁；人类遗传学和计算生物学高级副总裁。在GSK期间，他领导的团队专注于GSK治疗领域的大规模、工业化的目标发现和验证方法，包括呼吸系统、免疫学和炎症；肿瘤学；和传染病。在他的角色中，他汇集了人类遗传学、计算生物学、功能基因组学、化学生物学、结构生物学以及蛋白质和细胞科学，以推动药物发现和开发。在加入GSK之前，Ingelsson博士在2016年至2019年期间担任斯坦福大学的医学教授，他的实验室利用人类遗传学和功能基因组学发现了与胰岛素抵抗和相关疾病相关的新的生物学和药物靶点，例如肥胖、MASH和心血管疾病。他的工作将大规模的人类基因组学研究与深入的临床前验证工作和对心脏代谢疾病的重视相结合。Ingelsson博士此前曾于2013年至2016年担任瑞典乌普萨拉大学分子流行病学教授，并于2010年至2012年担任心血管流行病学教授，并于2008年至2010年担任瑞典卡罗林斯卡研究所流行病学副教授。在其职业生涯中，Ingelsson博士曾担任多家公共和私营公司的科学顾问和董事会成员。Ingelsson博士在瑞典乌普萨拉大学获得医学博士学位。他在马萨诸塞州波士顿的弗雷明汉心脏研究中心完成了博士后研究，并在瑞典的耶夫勒和乌普萨拉担任家庭医学的住院医师和研究金，之后他成为了10多年的执业临床医生。
- Erik Ingelsson has served as Chief Scientific Officer since May 2024. Prior to joining Wave Life Sciences, Inc., Dr. Ingelsson served as Senior Vice President, Head of Target Discovery; Senior Vice President of Genomic Sciences; and Senior Vice President of Human Genetics and Computational Biology at GSK during the period of January 2020 to May 2024. While at GSK, he led teams focused on a large scale, industrialized approach to target discovery and validation across GSK's therapy areas, including respiratory, immunology and inflammation; oncology; and infectious diseases. In his roles, he brought together human genetics, computational biology, functional genomics, chemical biology, structural biology, and protein and cellular sciences to drive drug discovery and development. Prior to joining GSK, Dr. Ingelsson was Professor of Medicine at Stanford University from 2016 to 2019, where his lab used human genetics and functional genomics to discover novel biology and drug targets related to insulin resistance and related conditions, such as obesity, MASH, and cardiovascular disease. His work combined large scale human genomics studies with in depth preclinical validation work and an emphasis on cardiometabolic diseases. Dr. Ingelsson previously served as Professor of Molecular Epidemiology at Uppsala University, Sweden from 2013 to 2016, and as Professor of Cardiovascular Epidemiology from 2010 to 2012, and as Associate Professor of Epidemiology from 2008 to 2010 at Karolinska Institute, Sweden. Over his career, Dr. Ingelsson has served as scientific advisor and board member for multiple public and private companies. Dr. Ingelsson earned his M.D. and Ph.D. at Uppsala University, Sweden. He completed postdoctoral research at the Framingham Heart Study in Boston, Massachusetts, and held residency and fellowship in Family Medicine at Gavle and Uppsala, Sweden, after which he was a practicing clinician for over 10 years.
- Chris Wright
Chris Wright自2025年5月起担任Wave Life Sciences，Inc.的首席医疗官。在加入Wave Life Sciences，Inc.之前，Dr. Wright于2023年2月至2025年5月期间担任基因治疗公司Ring Therapeutics，Inc.的首席医疗官，并于2021年5月通过2022年12月被Solid Biosciences Inc.收购的方式担任AavantiBio，Inc.的首席医疗官。从2019年4月到2021年3月，Wright博士担任Cyclerion Therapeutics, Inc.（“Cyclerion”）的高级副总裁兼首席医疗官，该公司是从Ironwood Pharmaceuticals, Inc.制药公司（“Ironwood”）公开分拆而来的上市公司，在那里他领导了跨治疗领域的全球开发职能。2017年3月至2019年4月，Dr. Wright担任Ironwood高级副总裁、首席开发官。在此之前，Wright博士曾担任Axcella Health公司的高级副总裁、首席医疗官以及Vertex Pharmaceuticals Incorporated公司的全球药物开发和事务高级副总裁，领导跨治疗领域的全球开发职能。Wright博士自2022年5月起担任全球生物制药公司阿尔凯默斯 PLC的董事会成员。Wright博士此前是哈佛医学院神经病学副教授，曾在布莱根妇女医院担任20年的执业神经科医生。他此前曾担任Cyclerion的科学顾问。Wright博士在哈佛大学获得了生化科学学士学位，在哈佛医学院获得了医学和神经科学医学博士学位，在荷兰自由大学获得了神经解剖学博士学位，并在哈佛医学院获得了临床研究硕士学位。
Chris Wright has served as Chief Medical Officer since May 2025. Before joining Wave Life Sciences, Inc., Dr. Wright served as Chief Medical Officer of gene therapy companies Ring Therapeutics, Inc. from February 2023 to May 2025 and AavantiBio, Inc. from May 2021 through its acquisition by Solid Biosciences Inc. in December 2022. From April 2019 to March 2021, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc. ("Cyclerion"), a publicly traded spin off from Ironwood Pharmaceuticals, Inc. ("Ironwood"), where he led global development functions across therapeutic areas. From March 2017 to April 2019, Dr. Wright served as Senior Vice President, Chief Development Officer of Ironwood. Prior to that, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated, where he led global development functions across therapeutic areas. Dr. Wright has served on the board of directors of Alkermes plc, a global biopharmaceutical company, since May 2022. Dr. Wright was previously an Associate Professor of Neurology at Harvard Medical School and was a practicing neurologist at Brigham and Women's Hospital for 20 years. He previously served as a Scientific Advisor for Cyclerion. Dr. Wright earned his A.B. in Biochemical Sciences from Harvard University, his M.D. in Medicine and Neuroscience from Harvard Medical School, his Ph.D. in Neuroanatomy from Vrije Universiteit in the Netherlands, and his MMSc. in Clinical Investigation from Harvard Medical School.- Chris Wright自2025年5月起担任Wave Life Sciences，Inc.的首席医疗官。在加入Wave Life Sciences，Inc.之前，Dr. Wright于2023年2月至2025年5月期间担任基因治疗公司Ring Therapeutics，Inc.的首席医疗官，并于2021年5月通过2022年12月被Solid Biosciences Inc.收购的方式担任AavantiBio，Inc.的首席医疗官。从2019年4月到2021年3月，Wright博士担任Cyclerion Therapeutics, Inc.（“Cyclerion”）的高级副总裁兼首席医疗官，该公司是从Ironwood Pharmaceuticals, Inc.制药公司（“Ironwood”）公开分拆而来的上市公司，在那里他领导了跨治疗领域的全球开发职能。2017年3月至2019年4月，Dr. Wright担任Ironwood高级副总裁、首席开发官。在此之前，Wright博士曾担任Axcella Health公司的高级副总裁、首席医疗官以及Vertex Pharmaceuticals Incorporated公司的全球药物开发和事务高级副总裁，领导跨治疗领域的全球开发职能。Wright博士自2022年5月起担任全球生物制药公司阿尔凯默斯 PLC的董事会成员。Wright博士此前是哈佛医学院神经病学副教授，曾在布莱根妇女医院担任20年的执业神经科医生。他此前曾担任Cyclerion的科学顾问。Wright博士在哈佛大学获得了生化科学学士学位，在哈佛医学院获得了医学和神经科学医学博士学位，在荷兰自由大学获得了神经解剖学博士学位，并在哈佛医学院获得了临床研究硕士学位。
- Chris Wright has served as Chief Medical Officer since May 2025. Before joining Wave Life Sciences, Inc., Dr. Wright served as Chief Medical Officer of gene therapy companies Ring Therapeutics, Inc. from February 2023 to May 2025 and AavantiBio, Inc. from May 2021 through its acquisition by Solid Biosciences Inc. in December 2022. From April 2019 to March 2021, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc. ("Cyclerion"), a publicly traded spin off from Ironwood Pharmaceuticals, Inc. ("Ironwood"), where he led global development functions across therapeutic areas. From March 2017 to April 2019, Dr. Wright served as Senior Vice President, Chief Development Officer of Ironwood. Prior to that, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated, where he led global development functions across therapeutic areas. Dr. Wright has served on the board of directors of Alkermes plc, a global biopharmaceutical company, since May 2022. Dr. Wright was previously an Associate Professor of Neurology at Harvard Medical School and was a practicing neurologist at Brigham and Women's Hospital for 20 years. He previously served as a Scientific Advisor for Cyclerion. Dr. Wright earned his A.B. in Biochemical Sciences from Harvard University, his M.D. in Medicine and Neuroscience from Harvard Medical School, his Ph.D. in Neuroanatomy from Vrije Universiteit in the Netherlands, and his MMSc. in Clinical Investigation from Harvard Medical School.